- $407.02m
- $497.71m
- $54.33m
- 16
- 21
- 46
- 16
Annual income statement for Carlsmed, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 27.6 | 54.3 |
| Cost of Revenue | ||
| Gross Profit | 9.9 | 20 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Total Operating Expenses | 64.7 | 103 |
| Operating Profit | -37.2 | -48.2 |
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -37.8 | -48.5 |
| Net Income After Taxes | -37.8 | -48.5 |
| Net Income Before Extraordinary Items | ||
| Net Income | -37.8 | -48.5 |
| Adjustments to Net Income | ||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -37.8 | -49.7 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -1.43 | -1.87 |